MOTS-c – Research Compound Profile

MOTS-c – Research Compound Profile

Category: Cellular Longevity & Metabolic Regulation | Molecular Type: Mitochondrial-Derived Peptide (16 amino acids) | Research Status: Preclinical + Phase 1 Analog Trial (CB4211)

This page compiles published research data for qualified researchers. MOTS-c is sold exclusively as a research compound, is not approved for human use, and this page does not constitute medical advice.

Purchase for Research →

Molecular Overview

MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA Type-c) is a 16-amino acid mitochondrial-derived peptide (MDP) encoded by a short open reading frame (sORF) within the 12S rRNA gene of mitochondrial DNA. Its amino acid sequence — MRWQEMGYIFYPRKLR — is highly conserved across 14 mammalian species, including humans and mice, underscoring its evolutionary importance in metabolic regulation [1]. MOTS-c was first identified in 2015 by Dr. Changhan David Lee and colleagues at the University of Southern California [1].

Unlike most mitochondrial gene products, MOTS-c is translated in the cytoplasm using the standard genetic code (mitochondrial translation would produce premature stop codons). Once translated, MOTS-c functions as a circulating “mitokine” — a mitochondrial-derived signal that acts on distant tissues in an endocrine-like fashion [13]. Endogenous MOTS-c levels have been reported to decline with age and to be lower in individuals with metabolic dysfunction, as documented in observational studies correlating circulating levels with BMI, insulin resistance markers, and HbA1c [6][7].

MOTS-c contains two methionine residues that are susceptible to oxidation, producing detectable metabolites at m/z 548 and 552, a property leveraged for doping-control mass spectrometry assays [9]. The hydrophobic core of the peptide (residues 8–11: YIFY) is critical for its nuclear binding and transcriptional activity [3].

Mechanism of Action

MOTS-c exerts its primary metabolic effects through the folate-purine-AMPK pathway. It suppresses de novo purine biosynthesis by inhibiting the folate cycle, leading to accumulation of the intermediate AICAR (5-aminoimidazole-4-carboxamide ribonucleotide), a potent endogenous AMPK activator [1][2]. Activated AMPK then drives a cascade of metabolic adaptations that have been described in the literature — increased glucose uptake into skeletal muscle, enhanced fatty acid β-oxidation, improved mitochondrial biogenesis, and suppression of lipogenesis.

Under conditions of metabolic stress, MOTS-c undergoes a remarkable behavior: it translocates from the mitochondria to the cell nucleus in an AMPK-dependent manner, where it interacts with antioxidant response element (ARE)-regulated transcription factors to reprogram nuclear gene expression [3]. This retrograde mito-nuclear signaling represents a fundamentally new communication pathway between mitochondria and the nucleus. In the nucleus, MOTS-c binds stress-responsive promoters via its hydrophobic core (residues 8–11: YIFY), driving expression of genes associated with oxidative-stress protection and cellular homeostasis [3]. This dual mechanism — cytoplasmic AMPK activation plus nuclear transcriptional regulation — is described in the literature as unusual among known metabolic regulators, and MOTS-c has been characterized in published reviews as a candidate “exercise mimetic” whose molecular signature overlaps with that of physical activity at the cellular level.

Skeletal muscle is the primary target tissue, where MOTS-c has been reported to enhance insulin-stimulated glucose disposal — the tissue responsible for the majority of insulin-mediated glucose uptake in mammalian physiology — and to activate the Akt signaling pathway [2]. Published research has also documented MOTS-c’s reported capacity to promote “browning” of white adipose tissue through thermogenic activation, alter energy expenditure independent of changes in food intake, and protect coronary artery endothelial cells through NF-κB-mediated anti-inflammatory signaling in preclinical models [2][14].

Exercise is reported to robustly induce endogenous MOTS-c — Reynolds et al. (2021) demonstrated that an acute bout of exercise substantially increases skeletal muscle MOTS-c levels, with circulating levels also rising and remaining elevated for a period after exercise [4]. This exercise-induction profile, combined with reported effects on physical capacity in aged murine models, has led to MOTS-c’s characterization in the literature as an exercise-induced mitochondrial-encoded regulator of physical capacity and aging [4].

Blood-brain barrier note: Peripherally administered MOTS-c does not cross the blood-brain barrier. Cognitive effects observed in preclinical models required central (intracerebroventricular) or intranasal administration with a cell-penetrating carrier [12].

Published Research Parameters

The following table indexes the study models, durations, and reported observations of selected peer-reviewed publications. Dose, frequency, and administration-route details are deliberately omitted. This is a bibliographic index only — not a protocol and not a recommendation for any use.

Stability & Storage Characteristics

Published data on MOTS-c stability and handling characteristics include:

• Lyophilized stability: Lyophilized MOTS-c maintains long-term stability at −20 °C (−4 °F) for 24+ months. Short-term storage at 2–8 °C (weeks) is acceptable for lyophilized material. Repeated freeze-thaw cycles should be avoided as they may compromise peptide integrity.
• Solution stability: High-resolution mass spectrometry analysis by Mohtashami et al. (2022) demonstrated no significant degradation of reconstituted MOTS-c stored at 4 °C for 30 days [8].
• Oxidation sensitivity: MOTS-c contains two methionine residues susceptible to oxidation under agitation or light exposure, producing detectable oxidized metabolites at m/z 548 and 552 [9]. Reconstituted solutions should be protected from light (stored in original packaging or wrapped in aluminum foil).
• Freeze-thaw considerations: Reconstituted solutions should not be frozen, as ice crystal formation may damage the peptide structure and reduce bioactivity.
• Recommended storage conditions for reconstituted material: 2–8 °C (35.6–46.4 °F), protected from light, with a recommended use window of up to 4 weeks based on the mass spectrometry stability data [8].

Analytical Characterization

Research-grade MOTS-c is characterized with an orthogonal analytical panel. Reverse-phase HPLC is the primary purity method and separates the intact 16-residue peptide from truncated synthesis by-products. High-resolution mass spectrometry confirms intact mass and, given the two methionine residues in the sequence, is used to quantify the mono- and di-oxidized species at m/z 548 and 552 relative to the parent ion — the principal degradation pathway reported for this peptide [9]. Because the peptide lacks a cyclic or disulfide-constrained structure, chiral purity (D-amino acid content from racemization during synthesis) is a further quality parameter tracked by chiral HPLC or GC-MS methods in peptide characterization generally. Researchers should retain the quality assurance documentation for each lot.

Key Published Research Findings

All findings below are derived from published peer-reviewed studies. Research status and model systems are noted for each.

• Insulin sensitization (preclinical): In a 2015 Cell Metabolism study, Lee et al. demonstrated that short-term MOTS-c administration restored insulin sensitivity in 12-month-old (middle-aged) mice toward levels observed in 3-month-old young mice, with a significant increase in skeletal muscle Akt pathway activation [1].

• Obesity prevention (preclinical): In the same 2015 study, Lee et al. reported that MOTS-c administration over 3 weeks prevented weight gain in high-fat diet-fed mice without affecting food intake. The effect was attributed to increased energy expenditure and enhanced fatty acid β-oxidation [1].

• Exercise performance in aging (preclinical): Reynolds et al. (2021) published in Nature Communications that aged mice (22–23.5 months old) treated with MOTS-c showed substantially longer and farther treadmill running performance compared to untreated controls [4].

• Lifespan extension signal (preclinical): In the same 2021 study, Reynolds et al. observed that mice treated with MOTS-c starting at 23.5 months of age showed a modest but statistically supported increase in both median and maximum lifespan relative to untreated controls [4].

• Nuclear translocation under stress (in vitro): Kim et al. (2018) published in Cell Metabolism that under metabolic stress conditions, MOTS-c translocates from the mitochondria to the cell nucleus in an AMPK-dependent manner, where it reprograms nuclear gene expression via antioxidant response element (ARE) promoters [3].

• Anti-inflammatory effects (preclinical): Yin et al. (2020) reported in the European Journal of Pharmacology that intraperitoneal MOTS-c significantly reduced pro-inflammatory cytokines (TNF-α, IL-1β, IL-6) and increased anti-inflammatory cytokine IL-10 in a mouse formalin model via AMPK activation and inhibition of ERK/JNK/p38 MAP kinase pathways [15].

• Cardiovascular protection (preclinical): Wei et al. (2020) published in Cardiorenal Medicine that MOTS-c reduced vascular calcification (calcium content) in a vitamin D/nicotine-induced calcification model via AMPK pathway activation [14]. Separately, Zhong et al. (2022) demonstrated in Journal of Cell and Molecular Medicine that MOTS-c mitigated heart failure development under pressure overload conditions in mice [16].

• Bone metabolism (preclinical): Ming et al. (2016) published in Biochemical and Biophysical Research Communications that MOTS-c administration over 12 weeks reduced ovariectomy-induced bone loss in mice through AMPK-mediated inhibition of osteoclast formation [17].

• Exercise synergy (preclinical): Yang et al. (2021) reported in BBA – Molecular Basis of Disease that MOTS-c combined with exercise synergistically regulated PGC-1α expression and attenuated insulin resistance in mice via AMPK signaling — the combination was reported to be more effective than either intervention alone [10].

• Sex-dependent responses (observational/preclinical): Preclinical and observational data indicate sex-dependent differences in MOTS-c dynamics. Males may exhibit greater MOTS-c disruption in metabolic disease contexts, while estrogen’s protective influence on mitochondrial biogenesis may modulate MOTS-c effects in pre-menopausal females [7][11].

• Longevity association (observational): Fuku et al. (2015) published in Aging Cell that MOTS-c functions as a circulating mitokine with potential associations with exceptional longevity, supporting the mitochondrial signaling hypothesis of aging [13].

Safety Profile in Published Literature

Clinical Trial Data (CB4211 Analog)

The most directly relevant human safety data come from the Phase 1a/1b trial of CB4211, a MOTS-c analog developed by CohBar Inc.:

• No serious adverse events were reported across Phase 1a (n=88) and Phase 1b (n=20) over a 4-week study period [5].
• The most commonly reported adverse effect was persistent painless injection site bumps — mild subcutaneous nodules that were non-serious but led to a temporary trial suspension and protocol amendment [5].
• No controlled clinical trials beyond 4 weeks have been completed for MOTS-c or its analogs. Long-term safety data are lacking.

Preclinical Toxicology

• Published preclinical studies in murine models have not reported significant toxicological findings across the exposure ranges evaluated [1][4].
• As a potent AMPK activator, MOTS-c shares overlapping pathways with metformin (folate cycle suppression, AMPK activation). Published literature notes the theoretical potential for potentiated glucose-lowering effects when combined with other AMPK activators [1][2].

Known Limitations

• No controlled clinical trials of exogenous MOTS-c peptide itself (as distinct from the CB4211 analog) have been completed in humans.
• Anecdotal reports referenced in anti-doping documentation include temporary increases in heart rate, insomnia, and low-grade fever, though these have not been confirmed in controlled studies.
• Peripheral MOTS-c does not cross the blood-brain barrier; only central or intranasal administration with cell-penetrating carriers has produced cognitive effects in preclinical models [12].

Regulatory Status

• FDA approval: MOTS-c is not approved by the FDA for human use.
• FDA Section 503A Category 2: As of September 2023, the FDA placed MOTS-c on the Section 503A Category 2 list, citing insufficient human exposure data to evaluate safety for compounded human use [18].
• Clinical trials: One Phase 1a/1b trial was completed for the analog CB4211 (NCT03998514) in healthy non-obese subjects and subjects with metabolic liver disease [5]. No further clinical trials are currently registered for MOTS-c or CB4211.
• Anti-doping: Mass spectrometry-based detection methods for MOTS-c have been developed for doping control purposes [9].
• MOTS-c is sold for research purposes only and is not intended for human consumption.

References

1. Cell Metabolism (2015) — Lee C, Zeng J, Drew BG, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metab. 21(3):443–454. View Source

2. Frontiers in Endocrinology (2023) — Zheng Y, Wei Z, Wang T. MOTS-c: A promising mitochondrial-derived peptide for therapeutic exploitation. Front Endocrinol. 14:1120533. View Source

3. Cell Metabolism (2018) — Kim KH, Son JM, Benayoun BA, Lee C. The mitochondrial-encoded peptide MOTS-c translocates to the nucleus to regulate nuclear gene expression in response to metabolic stress. Cell Metab. 28(3):516–524. View Source

4. Nature Communications (2021) — Reynolds JC, Lai RW, Woodhead JST, et al. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nat Commun. 12:470. View Source

5. ClinicalTrials.gov / CohBar Press Release (2021) — Phase 1a/1b Study of CB4211 in Healthy Non-obese Subjects and Subjects With Nonalcoholic Fatty Liver Disease. NCT03998514. Topline results: CB4211 met primary safety endpoint with no serious adverse events. View Source

6. Aging (Albany NY) (2020) — D’Souza RF, Woodhead JST, Hedges CP, et al. Increased expression of the mitochondrial derived peptide, MOTS-c, in skeletal muscle of healthy aging men is associated with myofiber composition. Aging. 12(6):5244–5258. View Source

7. Pediatric Diabetes (2018) — Du C, Zhang C, Wu W, et al. Circulating MOTS-c levels are decreased in obese male children and adolescents and associated with insulin resistance. Pediatr Diabetes. 19(6):1058–1064. View Source

8. Investigative Ophthalmology & Visual Science (2022) — Mohtashami Z, Ozgul M, Katz B, et al. Analysis of 1-month-old MOTS-c in H₂O; Using High Resolution Mass Spectrometry. IOVS. 63:474–A0011. View Source

9. Rapid Communications in Mass Spectrometry (2019) — Knoop A, Thomas A, Thevis M. Development of a mass spectrometry based detection method for the mitochondrion-derived peptide MOTS-c in plasma samples for doping control purposes. Rapid Commun Mass Spectrom. 33(4):371–380. View Source

10. Biochimica et Biophysica Acta – Molecular Basis of Disease (2021) — Yang B, Yu Q, Chang B, et al. MOTS-c interacts synergistically with exercise intervention to regulate PGC-1α expression, attenuate insulin resistance and enhance glucose metabolism in mice via AMPK signaling pathway. BBA Mol Basis Dis. 1867(6):166126. View Source

11. Journal of Molecular Medicine (2019) — Lu H, Wei M, Zhai Y, et al. MOTS-c peptide regulates adipose homeostasis to prevent ovariectomy-induced metabolic dysfunction. J Mol Med. 97:473–485. View Source

12. ADDF Cognitive Vitality Report (2025) — Alzheimer’s Drug Discovery Foundation. MOTS-c: Cognitive Vitality Evidence Summary. Peripheral MOTS-c is not BBB penetrant; central administration required for cognitive effects. View Source

13. Aging Cell (2015) — Fuku N, Pareja-Galeano H, Zempo H, et al. The mitochondrial-derived peptide MOTS-c: a player in exceptional longevity? Aging Cell. 14(6):921–923. View Source

14. Cardiorenal Medicine (2020) — Wei M, Gan L, Liu Z, et al. Mitochondrial-Derived Peptide MOTS-c Attenuates Vascular Calcification and Secondary Myocardial Remodeling via AMPK Signaling. Cardiorenal Med. 10:42–50. View Source

15. European Journal of Pharmacology (2020) — Yin X, Jing Y, Chen Q, et al. The intraperitoneal administration of MOTS-c produces antinociceptive and anti-inflammatory effects through the activation of AMPK pathway in the mouse formalin test. Eur J Pharmacol. 870:172909. View Source

16. Journal of Cell and Molecular Medicine (2022) — Zhong P, Peng J, Hu Y, et al. Mitochondrial derived peptide MOTS-c prevents the development of heart failure under pressure overload conditions in mice. J Cell Mol Med. 26:5369–5378. View Source

17. Biochemical and Biophysical Research Communications (2016) — Ming W, Lu G, Xin S, et al. Mitochondria related peptide MOTS-c suppresses ovariectomy-induced bone loss via AMPK activation. BBRC. 476(4):412–419. View Source

18. U.S. FDA (2023) — Certain Bulk Drug Substances Used in Compounding May Present Significant Safety Risks. FDA Section 503A Category 2 listing for MOTS-c. View Source

⚠️ Disclaimer: This page is provided for educational and informational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations. MOTS-c is sold exclusively as a research compound, has not been approved by the FDA for human consumption, and is not intended for human use or self-administration. As of September 2023, the FDA placed MOTS-c on Section 503A Category 2, citing insufficient safety data for compounded human use. All information is derived from published peer-reviewed literature. Research must comply with all applicable laws, regulations, and institutional guidelines.

Purchase MOTS-c for Research →